Richard Bernstein Advisors LLC Sells 3,856 Shares of McKesson Corporation $MCK

Richard Bernstein Advisors LLC reduced its holdings in McKesson Corporation (NYSE:MCK) by 49.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,930 shares of the company’s stock after selling 3,856 shares during the period. Richard Bernstein Advisors LLC’s holdings in McKesson were worth $3,036,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of McKesson by 2.0% in the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock valued at $8,846,186,000 after acquiring an additional 232,286 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of McKesson by 4.1% in the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock valued at $2,057,065,000 after buying an additional 112,224 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after purchasing an additional 1,362,386 shares during the period. Norges Bank bought a new stake in shares of McKesson in the 2nd quarter worth $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after purchasing an additional 446,060 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Trading Up 2.4%

McKesson stock opened at $941.19 on Tuesday. The company has a fifty day simple moving average of $884.77 and a 200-day simple moving average of $819.18. McKesson Corporation has a 12-month low of $633.53 and a 12-month high of $999.00. The stock has a market cap of $115.29 billion, a P/E ratio of 27.07, a price-to-earnings-growth ratio of 1.48 and a beta of 0.38.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, sell-side analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s payout ratio is 9.43%.

Insider Activity

In other news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michele Lau sold 2,725 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,868 shares of company stock valued at $3,743,820 in the last ninety days. 0.08% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on MCK. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Morgan Stanley reiterated an “overweight” rating and set a $966.00 price target on shares of McKesson in a report on Thursday, January 29th. Mizuho boosted their target price on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Robert W. Baird set a $968.00 price target on shares of McKesson in a report on Wednesday, January 14th. Finally, Wells Fargo & Company raised their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.